Results for Q4-2016

Oslo, 28 February 2017. Serodus announce the fourth quarter results.

SER150 Diabetic Nephropathy

  • Database locked late December
  • Positive results published 2. January 2017 on Phase 2a study both on primary and secondary endpoint
    • Statistically significant reduction of urine protein after 4-week treatment with 15 mg twice daily
    • Statistically significant reduction of urine protein after 4-week treatment with 30 mg twice daily
    • Very strong trend towards reduction of urine protein was observed compared to placebo treatment 

Finance and Investor Relations

  • Company received approval of delisting from Oslo Stock Exchange and is now a private company
Close Menu